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BACKGROUND: Prolonged high-dose anabolic-androgenic steroid (AAS) use has been associated with psychiatric
symptoms and cognitive deﬁcits, yet we have almost no knowledge of the long-term consequences of AAS use on
the brain. The purpose of this study is to investigate the association between long-term AAS exposure and brain
morphometry, including subcortical neuroanatomical volumes and regional cortical thickness.
METHODS: Male AAS users and weightlifters with no experience with AASs or any other equivalent doping
substances underwent structural magnetic resonance imaging scans of the brain. The current paper is based upon
high-resolution structural T1-weighted images from 82 current or past AAS users exceeding 1 year of cumulative
AAS use and 68 non–AAS-using weightlifters. Images were processed with the FreeSurfer software to compare
neuroanatomical volumes and cerebral cortical thickness between the groups.
RESULTS: Compared to non–AAS-using weightlifters, the AAS group had thinner cortex in widespread regions and
signiﬁcantly smaller neuroanatomical volumes, including total gray matter, cerebral cortex, and putamen. Both
volumetric and thickness effects remained relatively stable across different AAS subsamples comprising various
degrees of exposure to AASs and also when excluding participants with previous and current non-AAS drug abuse.
The effects could not be explained by differences in verbal IQ, intracranial volume, anxiety/depression, or attention or
behavioral problems.
CONCLUSIONS: This large-scale systematic investigation of AAS use on brain structure shows negative
correlations between AAS use and brain volume and cortical thickness. Although the ﬁndings are correlational,
they may serve to raise concern about the long-term consequences of AAS use on structural features of the brain.
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synthetic derivatives of the male sex hormone testosterone
that are primarily used in an illicit manner for cosmetic or
ergogenic purposes (1–3). Prolonged high-dose AAS use is
associated with a range of adverse health consequences,
including cardiovascular effects (4,5), psychiatric disorders (6–9),
and cognitive deﬁcits (10,11). Few studies have examined
potential brain structural alterations (12), which is critical
because AASs readily pass the blood-brain barrier and can
affect the central nervous system. Testosterone’s main activity
in the brain occurs via binding to cytoplasmic androgen
receptors (ARs) (13). ARs are widely distributed in the brain
and abundantly expressed in the brain stem, hypothalamus,
amygdala, hippocampus, and cerebral cortex (14–16), and these
regions are implicated in a wide range of functions, including the
regulation of emotion and cognition.
Supraphysiological doses of AASs may cause apoptotic
effects on a variety of cell types, including neurons (17–21),
may lead to impaired cognition in animal models (22,23), andN: 0006-3223
SEE COMMENTAare associated with lower cognitive function in humans (10).
These ﬁndings, coupled with reports of AAS-induced alterations
in mood and behavior (7,11), suggest that supraphysiologic
AAS doses may induce neurochemical or structural alterations
in the brain. This is supported by a recent neuroimaging study
of 10 AAS users that suggested that chronic AAS use was
associated with structural, neurochemical, and functional alter-
ations in the brain (12). In addition, other AAS-induced medical
effects may further threaten brain health. In particular, cardio-
vascular conditions—considered to be among the most serious
risks associated with AAS use—are known to be associated
with larger effects of age on brain structure (24), vascular brain
disease (25), cognitive decline (26), and dementia (26,27). These
cardiovascular effects associated with AAS use (5) with the
potential to compromise brain and cognition include hyper-
tension (24,28), atherosclerosis (29), and dyslipidemia (30).
Therefore, many indices suggest that prolonged AAS use with
supraphysiological doses may be associated with structural
alterations of the brain.& 2016 Society of Biological Psychiatry. 1
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Figure 1. Flow chart. AAS, anabolic-androgenic steroid users; MRI,
magnetic resonance imaging.
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PsychiatryWe examine the association between long-term exogenous
AAS exposure and brain morphometry. Male participants
engaged in heavy resistance strength training with or without
experience with AASs underwent structural magnetic reso-
nance imaging (MRI) scans of the brain. Based on the ﬁndings
of neurotoxic effects of supraphysiological AAS doses, neg-
ative relationships between AAS use and regional brain
volumes and cortical thickness are expected.
METHODS AND MATERIALS
Participants
The sample was drawn from the research project “Long-term
androgenic anabolic steroid use on brain structure, cognitive
functioning and emotional processing” coordinated from the
Department of Physical Medicine and Rehabilitation, at the
section of neuropsychology, Oslo University Hospital, Oslo,
Norway. The participants in the study are men engaged in
heavy resistance strength training belonging to one of the
following groups: 1) current or previous AAS users reporting
$1 year of cumulative AAS exposure (summarizing on-cycle
periods) and 2) men who have never tried AASs or equivalent
doping substances. Participants were recruited through a
Facebook project page; posts on Internet forums for body-
building, strongman, ﬁtness, and weightlifting; and forums
(open and closed) that directly target steroid users. In addition,
posters and ﬂyers were distributed in select gyms in Oslo. All
participants received an informational brochure with a com-
plete description of the study before participation, and written
informed consent was collected. The participants were com-
pensated for their participation with 1000 Norwegian kroner
(approximately $125).
In total, 159 men participated in the study, divided into 89
current or past AAS users and 70 nonusing controls. All
participants in the control group underwent MRI scanning,
but two participants were later excluded—one based upon the
radiological evaluation, and one because he did not match the
AAS group on strength and training regimens (with reported
maximum bench presses, squats, and deadlifts that were 2.6,
2.8, and 3.3 SDs below the sample mean, respectively). In the
AAS group, seven participants were excluded for various
reasons: three did not fulﬁll the criteria of having $1 year of
cumulative AAS exposure, one did not show up for the MRI
session, and another did not show up for the neuropsycho-
logical evaluation. In addition, MRI scan results could not be
obtained from two users, one because of a pacemaker implant
and one that experienced panic when approaching the
scanner (participant exclusion details can be found in
Figure 1). Our ﬁnal sample was 150 participants, with 82
current or previous AAS users and 68 nonusing controls.
Information about the material used and the ﬁndings in
relation to mapping the characteristics of AAS use, medical
history, and use of traditional use of drugs of abuse are
presented in the Supplement.
Doping Analysis
Urine samples were collected during the neuropsychological
evaluation and analyzed for AASs and narcotics using gas
chromatography and mass spectrometry at the World2 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalAnti-Doping Agency–accredited Norwegian Doping Laboratory
at the Oslo University Hospital, as described elsewhere (31).
Stimulants were analyzed with liquid chromatography and
mass spectrometry.
Brieﬂy, the criteria used to determine the use of AASs or
testosterone were as follows: 1) urine samples positive for
AAS compounds and 2) a testosterone to epitestosterone (T/E)
ratio . 15. A T/E ratio . 4 has been commonly applied by the
World Anti-Doping Agency as a population-based criteria for
samples requiring additional analysis with isotope ratio mass
spectrometry or follow-up to indicate testosterone abuse (32).
However, when applying this criterion in research and routine
analyses, cases of naturally occurring T/E ratios . 4 do appear
(33). Isotope ratio mass spectrometry analyses were not
performed in this study, and the stricter T/E ratio . 15 was
applied, which is equivalent according to Hullstein et al. (31).
Image Acquisition
MRI data were collected using a 3.0T Siemens Skyra scanner
(MAGNETOM Skyra; Siemens AG, Erlangen, Germany)
equipped with a 24-channel Siemens head coil. Anatomical
3-dimensional T1-weighted magnetization-prepared rapid
acquisition gradient-echo sequences were used for volumetry
and cortical surface analyses with the following parameters:
repetition time 5 2300 ms; echo time 5 2.98 ms; inversion
time 5 850 ms; ﬂip angle 5 81; bandwidth 5 240 Hz/pixel; ﬁeld
of view 5 256 mm; voxel size 5 1.0 3 1.0 3 1.0 mm; 176
slices sagittally oriented; acquisition time 5 9:50.
The magnetization-prepared rapid acquisition gradient-
echo sequences were our ﬁrst-priority sequence. The qualities
of these scans were immediately inspected at the scanning
session and rerun in case of movement in order to ensure that
the scans were of good quality. For one participant who was
anxious during the scanning, we could not run the sequence
again. However, this participant did not show up for the
neuropsychological evaluation, so he was omitted from the
dataset for another reason.
Imaging Analysis
All datasets were automatically processed and analyzed using
FreeSurfer software (version 5.3; http://surfer.nmr.mgh.harvard.
edu), which is described in detail elsewhere (34–39) (see
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PsychiatrySupplemental Methods for details). The cortical surface was
reconstructed for each subject to measure both surface area
and thickness at each surface location or vertex. The individual
thickness maps were smoothed using a Gaussian kernel of
15 mm. Subcortical volumes were obtained from the automatic
volume segmentation procedure (40,41), and we selected a
limited number of regions to limit the number of comparisons
that we needed to control for. The selection was done before the
statistical tests. The most commonly applied subcortical regions
that made sense theoretically were selected, including the
amygdala, accumbens area, thalamus, caudate, putamen, pal-
lidum, and hippocampus, and more global measures, such as
cortical volume, the lateral ventricle, cerebellum cortex, total
gray matter, and corpus callosum volume. The volumes from
both hemispheres of these structures were combined to gen-
erate a bilateral volume value. In addition, estimated intracranial
volume (ICV) (42) was computed and included in the analyses.
All reconstructed datasets were visually inspected and inaccur-
acies corrected when required.
Statistical Analyses
Group differences in demographic and neuropsychological data
were evaluated with two-tailed independent sample t tests and
χ2 tests for categorical data. Group differences in neuroanatom-
ical volumes were tested using general linear models (GLMs) with
regional volume as the dependent variable, group as the ﬁxed
factor, and age and ICV as covariates. Bonferroni-adjusted α-
level for correlated measures of 0.012 per test was applied (.05/
13, similar to a Pearson’s r 5 .43). For cortical thickness, we
ﬁtted a GLM at each vertex using thickness as the dependent
variable and age as the covariate. To reduce the possibility of
type I errors, a clusterwise correction using Z Monte Carlo
simulations with 10,000 iterations was performed. A cluster-
forming threshold of p , .05 (two-sided) was applied because
we expected anatomically broad and less spatially speciﬁc
effects. The stability of the main ﬁndings was also tested using
a cluster-forming threshold of p , .01 (two-sided) and by a false
discovery rate (FDR) of 5%. Similar exploratory analyses were
conducted for different subgroups of the sample (i.e., for
participants with prolonged AAS exposure, fulﬁlling the criteria
of AAS dependence, and for those with no additional non-AAS
drug abuse). To control for the possible inﬂuence of general
cognitive functions, aspects of mental health, and alcohol or
drug use on brain variables, we conducted analyses where the
Wechsler Adult Intelligence Scale vocabulary performance,
weekly reported alcohol consumption, Achenbach System of
Empirically Based Assessment Adult Self-Report T-scores for
anxious/depressed syndrome, drug use, attention problems, and
total problems were included as additional covariates (one at a
time). Moreover, within the AAS group, analyses were performed
to test for possible effects of degree of AAS exposure, use of
other drugs, or the status of use on brain measures.
RESULTS
Demographics and User Characteristics
Demographic data can be found in Table 1, and characteristics
of AAS usage are shown in Supplemental Table S1. The
groups did not differ in age, but both IQ and years ofeducation were lower in the AAS group. In the AAS group,
59 were current and 23 were previous users of AASs. A large
proportion of the AAS users and controls did not engage in
organized sports and could therefore be classiﬁed as recrea-
tional athletes. For the other study participants, weight training
was associated with participation in organized sports, with
bodybuilding, powerlifting, and combat sports being the most
popular categories. There were more bodybuilders in the AAS
group and powerlifters in the control group. Almost a quarter
(23.2%) of the AAS group and 35.3% of the control group
included participants who had placed in the top ﬁve compet-
itors in either national or international competitions. The AAS
group had a more frequent use of prescribed psychotropic
medications than the control group, with antidepressants and
anxiolytics being the most frequently prescribed. Of note, the
majority of AAS users and nonusers had never used pre-
scribed psychotropic medications of any kind (Table 1). The
groups also differed with regard to the presence of previous or
present comorbid substance abuse problems, and these were
more frequently observed in the AAS group. Information about
the use of illicit drugs is shown in Supplemental Table S3. In
general, the most frequently used substances were cocaine,
psychostimulants, and marijuana, whereas opiates were
uncommon, as conﬁrmed by the drug analyses (described in
the Supplement). Comparing the groups and including sub-
categories with current or previous non-AAS substance abuse
problems is suggestive of different drug habits in the different
groups. Several of the drugs, including tranquilizers, gamma-
hydroxybutyric acid, and hallucinogens, such as ecstasy and
lysergic acid diethylamide, were exclusively being used by the
AAS drug subgroup.
On average, AASs had been used for 9.1 years, and AASs
were commonly initiated during the participants' early 20s
(mean age 6 SD, 21.2 6 6.2 years). The reported weekly AAS
doses ranged from 125 to 7000 mg/week, with an average of
1278 mg/week (Supplemental Table S1).
Of the current AAS users (n 5 59), including those having
used AASs within the past 12 months, 80.7% had urine
samples that were positive for steroids (the T/E ratio was
not taken into account in this measure) (Table 2). Of the 11
current users with urine samples that were negative for AASs,
three had T/E ratios of 6.3 (this test was also positive for
antiestrogens), 9, and 47, respectively, that were consistent
with their reports of exogenous testosterone administration.
For seven participants, a few months had passed since their
last AAS cycle, thus compatible with the test observations.
One participant reported using low doses of trenbolone that
could not be documented and might reﬂect the use of
counterfeit steroids at the time of testing. This test was
positive for antiestrogens and there was no reason to doubt
his reports of use.
None of the control participants tested positive for steroids,
whereas two positive urine tests were found in the previous
user group. The positive tests could be related to the long
detection times of the compounds used. Still, to minimize
potential false reporting, replication analyses were carried out,
excluding one control subject with a suspiciously high T/E
ratio, current users with negative tests (n 5 9), and previous
users with positive tests (n 5 2). Excluding these only margin-
ally inﬂuenced the ﬁndings (Supplemental Figure S1).Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 3
Table 2. Percentage of Urine Samples Positive for AASs






n (%) T/E Ratio Range
Control 66 (2) 0 1.5 (1.5) 0.10–8.5
AAS Current 57 (2) 46 (80.7) 32.9 (42.9) 0.10–225.9
AAS Previous 22 (1) 2 (9.1) 2.5 (3.2) 0.6–14.7
AAS, anabolic-androgenic steroid; T/E, testosterone/epitestosterone.
Table 1. Demographics, Sports Information, Substance Abuse, and Use of Psychopharmaca
Attribute
AAS Group (n 5 82) Control Group (n 5 68)
Mean SD Mean SD t p Value
Age (Years) 33.0 8.2 31.4 9.1 –1.15 .252
Education (Years) 14.1 2.5 15.9 2.7 4.10 .000
IQ 104.9 12.0 112.9 9.4 4.53 .000
Cigarettes per Day 1.7 4.3 0.3 2.4 –2.42 .016
Alcohol Units per Week 1.7 3.2 3.3 4.8 2.38 .017
Height (cm) 180.7 6.9 180.9 6.7 0.23 .817
Weight (kg) 96.7 13.7 90.4 14.0 –2.87 .005
Body Mass Index (kg/m2) 29.6 4.1 27.6 4.0 –3.01 .003
Strength Training per Week (min) 351.5 206.7 467.0 241.9 3.13 .002
Endurance Training per Week (min) 124.7 194.1 92.0 112.8 –1.79 .204
Squats Max 217.2 57.4 172.3 41.5 –4.99 .000
Bench Max 168.6 30.8 135.6 32.0 –6.21 .000
Deadlift Max 231.8 49.1 198.8 45.1 –3.81 .000
Training Reason, n (%) χ2
Bodybuilding 20 (24.4) 4 (6.0) 9.26 .002
Fitness 1 (1.2) 2 (2.9) 0.21 .885
Weightlifting 0 (0) 3 (4.5) 3.75 .053
Powerlifting 1 (1.2) 15 (22.4) 17.24 .000
Combat sports 11 (13.4) 4 (6.0) 2.26 .133
Athletics 1 (1.2) 0 (0.0) 0.82 .364
Strongman 5 (6.1) 1 (1.5) 2.02 .155
Recreational 37 (45.1) 31 (46.3) 0.02 .889
Other (e.g., ball sports) 6 (7.3) 8 (11.9) 0.93 .336
Top 5 Achievement (Sport/Bodybuilding), n (%) 19 (23.2) 24 (35.3) 2.67 .102
Non-AAS Substance Abuse (Previous or Current), n (%) 33 (40.2) 3 (4.5) 25.74 .000
Psychopharmaca (Previous or Current Use), n (%)
Antidepressants 16 (20) 2 (3.0) 9.82 .002
Anxiolytics 14 (17.3) 0 (0.0) 12.79 .000
Opioids 4 (4.9) 0 (0.0) 3.41 .065
.1 type 6 (7.5) 0 (0.0) 5.16 .023
None reported 58 (71.6) 65 (97.0) 16.58 .000
AAS, anabolic-androgenic steroid.
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are shown in Supplemental Figure S2.
Associations Between AAS Use and Regional Brain
Volumetry
Neuroanatomical volumes in each group (whole AAS sample)
are presented in Table 3. Furthermore, neuroanatomical
volumes with effects surviving Bonferroni correction and
results when covarying for potential confounders and for
different subsamples are presented in Table 4. There were
no signiﬁcant differences in ICV between the groups, but ICV
was still regressed out from all group comparisons to ensure
that this did not inﬂuence the results. The AAS group had
signiﬁcantly smaller volumes on measures of total gray matter
volume, cortical volume, putamen volume (p # .012), and
corpus callosum (p 5 .013), although the latter did not reach
the Bonferroni-adjusted α-level. No group differences were
found for hippocampal or amygdala volume (Table 3).
The ﬁndings of smaller total gray matter and cortical volume
in the AAS group were marginally inﬂuenced by controlling for4 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalpotential confounders. In addition, the effect sizes remained
relatively stable across different AAS subsamples comprising
various degrees of exposure to AASs and other drugs of
abuse. Importantly, the differences were still signiﬁcant in
subsamples excluding participants with concurrent substance
abuse, but the effect sizes were somewhat reduced
(Supplemental Figure S3). The ﬁnding of smaller putamen
varied more across different sample reﬁnements and was not
Table 3. Group Differences in Brain Volumes Between AAS Users and Controls
Controls (n 5 68) All AAS users (n 5 82)
Mean SD Mean SD F p Value Partial η2
Cerebral Cortex 530,158 47,327 506,914 46,871 11.06 .001 0.07
Total Gray Matter 705,416 58,536 678,682 56,569 10.36 .002 0.07
Intracranial Volume 1,670,649 130,821 1,655,202 109,347 0.32 .575 0.00
Lateral Ventricles 17,100 8437 18,881 10,699 1.55 .215 0.01
Thalamus 15,874 1462 15,511 1347 1.14 .288 0.01
Caudate 8358 1093 7997 975 3.11 .080 0.02
Putamen 13,529 1681 12,801 1477 6.55 .012 0.04
Pallidum 3268 439 3236 453 0.09 .768 0.00
Hippocampus 9351 846 9280 895 0.00 .960 0.00
Amygdala 4088 468 4014 496 0.29 .588 0.00
Accumbens 1627 239 1541 237 3.07 .082 0.02
Corpus Callosum 3456 460 3274 409 6.27 .013 0.04
Cerebellar Cortex 110,392 10,421 108,528 11,441 0.16 .69 0.00
Values are mm3.
General linear models were performed with neuroanatomical volume as the dependent variable, group as the ﬁxed factor, and age and
intracranial volume as continuous covariates. All effects were in the form of smaller volumes in the anabolic-androgenic steroid (AAS) group.
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symptoms of anxiety/depression, and a summarized measure
of behavioral problems. It was also not signiﬁcant when
restricting the analyses to previous AAS users or AAS users
with $10 years of AAS exposure (Table 4).
Associations Between AAS Use and Cortical
Thickness
Figure 2 and Table 5 show the results from the corrected GLM
analyses comparing differences in cortical thickness between the




All VIQ Regressed out (n 5 82) 506,914 (46,871) 8.25
All Weekly Alcohol Regressed Out (n 5 80) 506,421 (47,297) 12.69
All ASR Drugs Regressed Out (n 5 67) 508,167 (46,068) 7.71
All ASR Anxious/Depressed Regressed Out (n 5 69) 507,716 (46,384) 5.22
All ASR Attention Problems Regressed Out (n 5 69) 507,444 (45,398) 8.75
All ASR Total Problems Regressed Out (n 5 65) 505,126 (45,168) 5.17
Current Users (n 559) 501,319 (48,625) 11.85
Previous Users (n 5 23) 521,267 (39,445) 2.53
≥5 Years (n 5 65) 503,060 (44,278) 13.80
≥5 Years With No Additional Drug Addictiona (n 5 38) 506,042 (43,627) 4.25
≥10 Years (n 5 32) 499,203 (45,041) 7.13
≥10 Years With No Additional Drug Addictiona (n 518) 492,786 (42,037) 1.52
AAS Dependence (n 544) 502,838 (46,158) 13.90
AAS Dependence With No Additional Drug Addictiona
(n 5 22)
503,386 (47,455) 4.97
n Denotes the number of participants in the AAS subgroup included in
ASR, Adult Self-Report; VIQ, verbal IQ.
aAnalyses where anabolic-androgenic steroid (AAS) users and controls
n 5 68 aside from the no additional drug addiction conditions (n 5 65).panel), which included all participants, AAS users had signiﬁcantly
thinner cortex bilaterally. Five clusters were found in the left
hemisphere and three clusters in the right hemisphere. The largest
cluster in the left hemisphere covered part of the inferior and
superior parietal lobe as well as lateral and medial occipital
regions, and the cuneus. Other clusters with thinner cortex in
the AAS users comprised (ranked from largest to smallest)
superior temporal areas, the posterior cingulate, precentral and
medial frontal gyrus, and ﬁnally a cluster covering a smaller part of
the postcentral gyrus corresponding to Brodmann area 43.
The signiﬁcant clusters in the right hemisphere corre-
sponded to some degree to the clusters of the leftControls and Various Anabolic-Androgenic Steroid User
x Total Gray Matter Putamen
p
Value mm3 (SD) F
p
Value mm3 (SD) F
p
Value
.005 678,682 (56,569) 8.092 .005 12,801 (1477) 6.655 .011
.001 678,324 (57,218) 11.38 .001 12,779 (1476) 7.31 .008
.006 680,380 (54,152) 6.92 .010 12,953 (1402) .94 .334
.024 679,948 (55,509) 4.55 .035 12,991 (1404) 1.40 .239
.004 679,703 (53,327) 7.34 .008 13,020 (1402) 3.25 .074
.025 676,808 (52,914) 4.74 .031 12,904 (1353) 1.98 .160
.001 671,367 (58,016) 12.01 .001 12,679 (1463) 6.51 .012
.116 697,445 (48,958) 1.63 .206 13,114 (1499) 1.98 .163
.000 674,876 (53,936) 11.75 .001 12,758 (1512) 5.04 .027
.042 676,133 (53,074) 4.25 .042 12,504 (1448) 7.03 .009
.009 668,009 (54,761) 7.40 .008 12,824 (1575) .21 .650
.221 655,133 (47,815) 3.20 .078 12,369 (1277) .48 .491
.000 676,604 (54,303) 10.94 .001 12,749 (1457) 6.49 .012
.028 675,333 (55,018) 4.18 .044 12,468 (1428) 6.60 .012
each subanalysis. Values are mm3 (SD).
with concurrent substance abuse are omitted. For the control group,
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Figure 2. Vertexwise comparisons of cortical thickness between the
control group and various anabolic-androgenic steroid (AAS) subsamples.
The results show comparisons between the following groups: AAS users
(n 5 82) and controls (n 5 68) (row 1); controls (n 5 64) and AAS users
exceeding 5 (n 5 38) (row 2) or 10 years (n 5 18) (row 3) of AAS use without
concurrent non-AAS substance abuse; and controls (n 5 68) with current
(n 5 59) (row 4) and previous (n 5 23) (row 5) AAS users. Shades of blue
indicate clusters with thinner cortices in the AAS group. No effects were
seen in the opposite direction (i.e., thicker cortices).
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Psychiatryhemisphere, but with some exceptions. The three clusters
were of similar size and were located in the cuneus, the
precentral gyrus, and some minor parts of the inferior frontal
and superior frontal gyrus, and in temporal areas, including the
temporal pole and the inferior, medial, and superior temporal
gyrus. Regressing out verbal IQ, drug use, weekly alcohol
consumption, symptoms of anxiety and depression, attention
problems, and total problem scores had a marginal inﬂuence
of the differences in thickness between users and nonusers
(Supplemental Figure S4).
Exploratory analyses based on reﬁnements of the AAS
sample—done in order to focus on those with a longer history
of AAS use—were suggestive of more widespread effects.
This was particularly apparent in users with ≥10 years of AAS
exposure and for those fulﬁlling the criteria for AAS depend-
ence (Supplemental Figure S5 and Table S4). Characteristic
ﬁndings after longer and more severe exposure were larger
clusters in occipital, temporal, parietal, and frontal areas,
which suggest that group differences after protracted AAS
exposure are global. Group differences were now also seen in
large frontal cortical regions and in the left cingulate. Similar
ﬁndings were seen when excluding participants with concur-
rent substance abuse, particularly for those with ≥10 years of
AAS exposure, although some clusters were smaller or did not
survive corrections. The main ﬁndings employing a cluster-
forming threshold of p , .01 and FDR correction are shown in
Supplemental Figures S6 and S7 and Supplemental Table S5.6 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalMoreover, as the choice of smoothing kernel might inﬂuence
the ﬁndings, the main ﬁndings using the higher smoothing
level of 30 mm (both uncorrected and FDR-corrected) are
shown in Supplemental Figure S8. Note that more effects
survive FDR correction by applying this higher smoothing
level.
Similar clusters were also found when restricting the
analysis to current AAS users. For previous users, thinner
cortex was seen bilaterally in the precentral gyrus and in the
left superior parietal cortex (Figure 2 and Table 5). The effects
were more widespread in current users, but statistical power
was higher for this group. Analyses comparing previous
(n 5 23) and current (n 5 59) users showed only minor differ-
ences, with thinner cortex in the current users in parts of the
parahippocampal and lateral occipital cortex in the left hemisphere
(Supplemental Figure S9 and Supplemental Table S6).
Analyses comparing AAS users with long-term AAS expo-
sure ($10 years; n 5 32) to those with shorter exposure (#5
years; n 5 23) showed that longer exposure was associated
with thinner cortex in widespread regions, including the
isthmus and posterior cingulate, middle and inferior temporal
regions, and a frontal cluster, including rostral middle frontal
regions, pars opercularis, and the medial orbitofrontal cortex.
Finally, the combination of drug abuse with AAS use was
associated with more widespread thinning, particularly in the
cuneus, superior frontal, and orbitofrontal regions of the left
hemisphere, and one cluster in the supramarginal gyrus of the
right hemisphere (Supplemental Figure S9).DISCUSSION
In the ﬁrst large systematic neuroimaging investigation of AAS
users, we found smaller overall gray matter, cortical and
putamen volume, and thinner cortex in widespread regions
in AAS users compared to nonusing weightlifters. Generally,
stronger effects were seen with an increasing burden of AAS
exposure and in users without any other substance abuse
problems. Possible implications of the results are discussed
below.
Thinner and Smaller Cortex Associated With AAS
Use
AAS users had smaller overall cortical volume and thinner
cortex in widespread regions, and this was relatively stable
across different subsamples. The effects were more wide-
spread after longer use. The effects on cortical thickness and
volume could not be explained by concurrent substance
abuse, although drug abuse in combination with AAS use
was associated with even larger cortical effects than AAS
use alone.
One previous study reviewed associations between long-
term AAS use and brain morphometry, and suggested that
chronic AAS use could be associated with enlargement of the
right amygdala (12), consistent with the primary action of
steroids acting on androgen receptors, which are highly
expressed in the amygdala (15). In the present study, we could
not replicate the ﬁndings regarding the amygdala. Instead,
smaller volumes and thinner cortex throughout were seen in
the AAS group. For brain volumes, the strongest group effects
Table 5. Differences in Cortical Thickness Between Various AAS User Subsamples and the Control Group
Talairach Coordinates
Cortex Area Cluster Size (mm2) x y z CWP
All Included
Left inferior parietal 11,253.03 –36.5 –84.4 21.7 0.00010
Left posterior cingulate 2332.27 –11.1 –11.6 40.0 0.00170
Left superior temporal 4176.67 –44.0 6.8 –24.6 0.00010
Left superior frontal 1540.41 –7.0 38.9 48.4 0.02770
Left precentral 2059.62 –22.4 –23.2 63.7 0.00500
Right cuneus 6796.20 9.1 –66.0 13.6 0.00010
Right precentral 5358.84 53.9 –2.7 28.7 0.00010
Right superior temporal 5884.78 57.9 –10.8 –5.1 0.00010
≥5 Years With No Drugs
Right cuneus 3437.14 4.1 –69.0 15.6 0.00010
Right superior temporal 2405.88 53.6 –13.9 –6.9 0.00110
≥10 Years With No Drugs
Left posterior cingulate 4254.27 –12.7 –15.7 38.5 0.00010
Left fusiform 19,776.99 –27.9 –55.8 –16.1 0.00010
Right middle temporal 9072.23 54.1 –30.8 –17.2 0.00010
Right cuneus 3591.47 12.1 –67.6 16.2 0.00010
Right precentral 2371.46 55.8 –2.4 36.0 0.00140
Right middle temporal 1607.63 51.8 –57.6 1.2 0.02350
Current Users
Left inferior parietal 13,995.15 –35.7 –82.7 24.4 0.00010
Left superior temporal 5169.37 –46.0 3.9 –21.6 0.00010
Left fusiform 1702.65 –27.3 –50.1 –17.0 0.01510
Left superior frontal 1405.15 –6.2 42.0 44.9 0.04500
Right cuneus 7477.24 10.1 –65.9 13.1 0.00010
Right precentral 3426.04 54.1 –2.8 29.3 0.00010
Right insula 8132.27 36.0 –17.5 12.1 0.00010
Previous Users
Left precentral 4061.93 –32.1 –16.2 67.0 0.00010
Left superior parietal 2375.72 –22.0 –61.7 60.9 0.00010
Right precentral 4611.91 57.1 5.3 13.2 0.00010
The cortical area, the size of the signiﬁcant cluster, Talairach coordinates corresponding to the most signiﬁcant vertex within each cluster, and
clusterwise p values (CWPs) are shown. All ﬁndings are in the direction of thinner cortices in the anabolic-androgenic steroid (AAS) group.
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Psychiatryapplied to the global measures of cerebral cortex and total gray
matter volume. Group differences were also found for putamen,
a large structure of the basal ganglia. These effects could reﬂect
an association between long-term AAS exposure and less brain
tissue in general rather than with more region-speciﬁc effects. In
general, stronger effects were observed after prolonged expo-
sure, and this was particularly evident in those who met the
requirements for AAS dependence. Within-group analyses also
conﬁrmed that a longer history of AAS exposure was associated
with thinner cortex in the frontal, temporal, parietal, and occipital
regions compared to subjects with shorter exposures. Our
ﬁndings might indicate that use of AAS is associated with a
risk of progressive deterioration of cerebral tissue, and that this
is particularly evident after prolonged heavy use. It has been
shown that supraphysiological doses of testosterone and
commonly abused AASs can induce apoptosis on a variety of
mammalian cell types, including neurons (17,18,20,43). The
mechanisms behind possible AAS-induced neurotoxicity areunclear, but amyloid-beta aggregation and increased suscept-
ibility to oxidative stress have been suggested (17–20,44–46).
Cardiovascular effects are among the most serious adverse
effects associated with AAS use (24,28–30) that again have
been linked with accelerated brain aging (24,47,48), vascular
brain disease (25), cognitive decline (26), and dementia (26,27).
Another potential mechanism behind our ﬁndings could be
related to AAS-induced cardiovascular effects and associated
risks to compromise brain health.
Prolonged AAS use has been associated with a range of
psychiatric symptoms and disorders (6–9) and recently also
with cognitive deﬁcits (10), and our ﬁndings could potentially
constitute brain correlates of such deviations. However, the
nature of such relations are complex, not least of all because it
is difﬁcult to distinguish what is caused by premorbid psycho-
logical characteristics and what is a direct cause of AAS use.
Our knowledge of adverse health consequences of AASs
primarily comes from ﬁeld studies (49). In addition, for aBiological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 7
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Psychiatryproportion of users, AASs are used in conjunction with other
drugs of abuse (50–52), and studies usually do not separate
users with more clean AAS use from those with combined AAS
and non-AAS substance abuse. This is of importance not only
in order to understand the consequences of AAS use per se,
but also to grasp the potential health consequences of a
lifestyle consisting of hard weight training in combination with
hormone and polydrug abuse.
Our ﬁndings could not be explained by differences in verbal
cognitive function (i.e., verbal intelligence) or ICV. Verbal
intelligence can be argued, at least to some degree, to reﬂect
premorbid cognitive functions. ICV reﬂects premorbid brain
volume, and the lack of ICV differences between the groups
indicates that the volumetric effects seen emerged after the
volume of the brain was fully developed. The fact that the
cortical group effects survived controlling for verbal intelli-
gence and ICV may indicate that the AAS exposure itself could
be causing the effects on the cerebral cortex. In addition, there
were also group differences when users with additional non-
AAS substance abuse were omitted, and after controlling for
other potential confounders, such as weekly alcohol con-
sumption, recent use of illegal drugs, anxiety/depression,
attention problems, or global indices of behavioral problems.
In addition, the within-group ﬁndings of thinner cortex after
longer history of AAS use raise the ominous possibility that the
observed group differences are the result of AAS-induced
cerebral atrophy. The underlying mechanisms are not known
but could involve direct AAS-induced neurotoxicity or more
indirect mechanisms through AAS side effects on the cardio-
vascular system. However, these are speculations, and the
present design does not allow drawing deﬁnite conclusions
regarding causality beyond the correlational results described.
Limitations
Important limitations of the study include the use of a cross-
sectional, retrospective design, which means that we do not
know whether differences in brain morphometry also existed
before AAS initiation. We also cannot rule out the inﬂuence of
genetic effects or the possibility that AAS use is associated
with other lifestyle risk factors that might inﬂuence brain
volume.
Conclusions
Although correlational, our ﬁndings of thinner and smaller
cortices associated with AAS exposure raise concerns about
possible deleterious effects of long-term AAS use on brain
health. The cortical effects seemed to persist after stopping
AAS use. Understanding the impact of AAS use on brain and
its cognitive and psychiatric correlates is important in order to
safeguard the needs of the growing numbers of long-term AAS
users now entering middle age. Large-scale longitudinal—and
ideally prospective—studies are warranted to address the
possible implication of accelerated cerebral atrophy caused
by long-term AAS exposure.
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